Compare · ABT vs PHVS
ABT vs PHVS
Side-by-side comparison of Abbott Laboratories (ABT) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 72.0x PHVS ($2.43B).
- Both names hit the wire about 10 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Abbott Laboratories
- Pharvaris N.V.
- Price
- -
- -
- Market cap
- $175.37B
- $2.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest PHVS
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)
- Wells Fargo initiated coverage on Pharvaris N.V. with a new price target
- Chief Medical Officer Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.34% to 65,405 units (SEC Form 4) (tax withholding)
- SEC Form 144 filed by Pharvaris N.V.
- Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
- Director Schikan Johannes Gerardus Christiaan Petrus sold $1,331,496 worth of shares (37,600 units at $35.41) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 315,167 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 38,472 shares at a strike of $6.85 and sold $2,695,452 worth of shares (76,172 units at $35.39) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 58,750 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 2,300 shares at a strike of $4.73 and sold $161,560 worth of shares (4,600 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $84,250 worth of shares (2,400 units at $35.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 352,767 units (SEC Form 4)
- Chief Medical Officer Lu Peng exercised 29,700 shares at a strike of $2.59 and sold $1,018,832 worth of shares (29,700 units at $34.30) as part of a pre-agreed trading plan (SEC Form 4)